Liposomal Irinotecan

Org: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Wake Forest University Department of General Internal Medicine, Stanford University School of Medicine, ThedaCare Regional Medical Center,

Abstract

A randomised phase 2 study of liposomal irinotecan in combination with 5-fluorouracil/leucovorin and oxalipalatin versus nab-paclitaxel plus gemcitabine in unresectable locally advanced or metastatic pancreatic cancer.

Org: Liaoning Cancer Hospital, Shenyang, China, Affiliated Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Yunnan Cancer Hospital, Yunnan, China, CSPC Ouyi Pharmaceutical Technology (Shijiazhuang) Co.,Ltd, Shijiazhuang, China,

Abstract

Alliance EAY191-A6: FOLFOX in combination with binimetinib as second-line therapy for patients with advanced biliary tract cancers (BTCs) with MAPK pathway alterations: A ComboMATCH treatment trial.

Org: The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Trinity Health IHA Medical Group,

Abstract

Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.

Org: Gastrointestinal and Endocrine Tumor Unit Vall d'Hebron University Hospital and Vall d'Hebrón Institute of Oncology (VHIO), Barcelona, Spain, Yale University School of Medicine, New Haven, CT, Sheba Medical Center, Ramat Gan, and Tel Aviv University, Tel Aviv, Israel, Rambam Medical Center, Haifa, Israel, HonorHealth Research Institute, Scottsdale, AZ,

Clinical trial

A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Liposomal Irinotecan in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)

Status: Active (not recruiting), Estimated PCD: 2023-09-16

Clinical trial

A Phase II Study to Evaluate the Efficacy of Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI15-067

Status: Active (not recruiting), Estimated PCD: 2023-08-16

Clinical trial

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients With Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

Phase 2 Single-Arm Study of Nanoliposomal Irinotecan With Fluorouracil and Leucovorin in Refractory Advanced High Grade Neuroendocrine Cancer of GI, Unknown or Pancreatic Origin

Status: Active (not recruiting), Estimated PCD: 2022-10-18

Clinical trial

Study of Irinotecan Liposome Combined With Anlotinib as Second-line Regimen in Patients With Small Cell Lung Cancer

Status: Not yet recruiting, Estimated PCD: 2025-04-01

Clinical trial

A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers

Status: Recruiting, Estimated PCD: 2024-11-28

Clinical trial

Exploratory Study of Irinotecan Liposomes Combined With Bevacizumab in Maintenance Therapy of Metastatic Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing Sarcoma

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer: a Phase Ib/II, Multicenter, Open-label Trial

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

HR070803 in Combination With Oxaliplatin Plus Tegafur Versus HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate as Adjuvant Therapy for Pancreatic Cancer: A Multicenter, Multi-cohort, Randomized, Phase II Study

Status: Not yet recruiting, Estimated PCD: 2027-03-01

Clinical trial

Phase II Study of the Combination of Liposomal Irinotecan (Nal-IRI) and Pembrolizumab for Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Status: Withdrawn, Estimated PCD: 2027-01-31

Clinical trial

Efficacy and Safety of Irinotecan Liposome Injection Combined With Oxaliplatin and Tegafur (NASOX) in Adjuvant Chemotherapy for Pancreatic Cancer

Status: Recruiting, Estimated PCD: 2025-03-25

Clinical trial

A Multi-centre, Randomised, Parallel Group, Open-label, Phase II, Single-stage Selection Trial of Liposomal Irinotecan (Nal-IRI) and 5-fluorouracil (5-FU)/Folinic Acid or Docetaxel as Second-line Therapy in Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma (NEC))

Status: Active (not recruiting), Estimated PCD: 2023-12-01

Clinical trial

A Phase II and III, Randomized, Multicenter Clinical Study: Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy Strategy

Status: Recruiting, Estimated PCD: 2023-12-31

Clinical trial

Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer

Status: Active (not recruiting), Estimated PCD: 2023-12-31

Clinical trial

Phase II Study of Irinotecan Liposomes Combined With 5-FU/LV+ Bevacizumab in First-line Treatment of Metastatic Colorectal Cancer

Status: Not yet recruiting, Estimated PCD: 2026-04-01

Clinical trial

PD-1 Inhibitor Plus Chemotherapy as Conversion Therapy in Unresectable Gastric Cancer (STARS-GC01): A Single-arm, Single-center, Prospective Clinical Study.

Status: Completed, Estimated PCD: 2023-05-06

Clinical trial

Efficacy and Safety of Toripalimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma: a Multicenter, Randomized, Phase II Trial (EC-CRT-007)

Status: Recruiting, Estimated PCD: 2026-12-31

Clinical trial

Fruquintinib Combined With S-1 and Raltitrexed for Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study

Status: Recruiting, Estimated PCD: 2024-06-18

Clinical trial

A Prospective, Multi-cohort, National Multicenter Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan

Status: Recruiting, Estimated PCD: 2026-07-01

Abstract

Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC).

Org: Servier Deutschland GmbH, Clinasses Inc, Clinassess Inc., Klinik und Poliklinik für Chirurgie, General and Visceral Surgery,

Abstract

Adding mitomycin (MM) to bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non–muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301.

Org: UWA Medical School, University of Western Australia & Linear Clinical Research, NHMRC Clinical Trials Centre, The University of Sydney, Fiona Stanley Hospital and Edith Cowan University,

Abstract

OniLon: Phase II trial of trifluridine/tipiracil (TAS-102) and nanoliposomal irinotecan (nal-IRI) in advanced colorectal cancer.

Org: Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute, Emory University School of Medicine, Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA,

Abstract

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma: NEO-Nal-IRI study.

Org: University of Florida/UF Health Cancer Center, University of Florida Health Cancer Center, Orlando Health Cancer Institute, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,

Abstract

Efficacy of vemurafenib based regimens in colorectal cancer: A systematic review of clinical trials.

Org: New York Medical College - Saint Michael's Medical Center, Saint Michael's Medical Center, St. Michael's Medical Ctr, Reg Cancer Ctr At St Michael's Medical Ctr,

Abstract

Survival outcomes of liposomal irinotecan in patients with advanced pancreatic adenocarcinoma previously treated with conventional irinotecan-based chemotherapy: A single-institution experience.

Org: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Baltimore, MD,

Product

Lurbinectedin + Irinotecan

Product

nal-IRI plus S-1

Product

NALIRIFOX

Product

liposomal irinotecan (nal-IRI) with 5-fluorouracil/leucovorin (5-FU/LV)

Product